Fundraising FoxNavega Therapeutics
San Diego, US · Delaware corporation
Find your way into Navega Therapeutics
Sign up to see every warm intro you have to Navega Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Navega Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Navega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
Founders & leadership
FA
Fernando AlemanCo-founder and CSOFernando Aleman is Co-founder and Chief Scientific Officer of Navega Therapeutics, where he leads scientific strategy for gene therapy programs targeting neurological and ophthalmic diseases. He has over a decade of experience in molecular biology and biochemistry across academic and industry roles.
RS
Randy SocolExecutive
Funding
SEC filings, press & company announcements$1.3M disclosed across 1 of 2 rounds · 2024–2026
- Undisclosed amountSeries ANov 2024Source ↗
▶$1.3MraisedJan 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJan 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy SocolExecutive Officer
- Fernando AlemanExecutive Officer, Director
- Ana MorenoExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.3M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Abeona TherapeuticsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Nava TherapeuticsNava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
Jnana TherapeuticsJnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Averna TherapeuticsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
OrnaOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Companies working in the same space as Navega Therapeutics.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $275.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $624.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $288.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Navega Therapeutics do?
- Navega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
- Who founded Navega Therapeutics?
- Navega Therapeutics was founded by Fernando Aleman, Ana Moreno.
- How much funding has Navega Therapeutics raised?
- Navega Therapeutics has disclosed $1.3M raised across 1 of its 2 known rounds.
- Where is Navega Therapeutics headquartered?
- Navega Therapeutics is headquartered in San Diego, US.